<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-158448</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Spironolactone, a therapeutic alternative in the treatment of diffuse retinal pigment epitheliopathy</dc:title>
<dc:description xml:lang="en">Two cases are presented of patients with chronic diffuse epitheliopathy (CDE) that showed a favourable response when treated with spironolactone. The first patient had regions of neurosensory detachment (DNS) and the second, multiple DNS, secondary intra-retinal cysts and retinal pigment epithelium detachment. Discussion. After treatment with spironolactone, both patients showed a visual acuity improvement and structural changes (reduced neurosensory retinal detachment and cystoid degeneration). Aldosterone receptor agonists (ARA) used for persistent forms of chronic central serous chorioretinopathy show encouraging results and could represent a therapeutic alternative for CDE (AU)</dc:description>
<dc:creator>Losada Castillo, MJ</dc:creator>
<dc:creator>Abreu Reyes, JA</dc:creator>
<dc:creator>Cordovés-Dorta, L</dc:creator>
<dc:creator>Blasco Alberto, A</dc:creator>
<dc:creator>Ángel-Pereira, D</dc:creator>
<dc:creator>Rocha-Cabrera, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Se presentan 2 casos clínicos de epiteliopatía difusa crónica (EDC) con respuesta favorable a espironolactona. En el primer paciente se visualizan regiones de desprendimiento neurosensorial (DNS), y en el segundo múltiples DNS, quistes intrarretinianos secundarios y desprendimiento del epitelio pigmentario de la retina. Discusión. Tras el tratamiento con espironolactona, se observa mejoría de la agudeza visual y de las alteraciones estructurales en ambos pacientes (disminución del DNS y quistes intrarretinianos). Los fármacos antagonistas de los receptores de aldosterona usados para formas persistentes de coriorretinopatía central serosa (CRCS) tienen resultados alentadores, y podrían ser una alternativa terapéutica en la EDC (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;91(12): 599-603, dic. 2016. ilus</dc:source>
<dc:identifier>ibc-158448</dc:identifier>
<dc:title xml:lang="es">Espironolactona, alternativa terapéutica en el tratamiento de la epiteliopatía difusa crónica</dc:title>
<dc:subject>^d53529^s22009</dc:subject>
<dc:subject>^d12578^s22009</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d453^s22073</dc:subject>
<dc:subject>^d53529^s22012</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12578^s29166</dc:subject>
<dc:subject>^d13531^s22073</dc:subject>
<dc:subject>^d4927^s29166</dc:subject>
<dc:subject>^d4927^s22009</dc:subject>
<dc:subject>^d12578^s22042</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d24366^s22031</dc:subject>
<dc:type>article</dc:type>
<dc:date>201612</dc:date>
</metadata>
</record>
</ibecs-document>
